Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltuximab and Spartalizumab in Metastatic Pancreatic Cancer
NCT04191421Phase 2Completed
- Sponsor
- Emory University
- Start
- Jan 2020
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of siltuximab in pancreatic cancer (PC) (4 arms), sponsored by Emory University. Primary endpoint: Maximal Tolerated Dose at 6 weeks. Started Jan 2020; status: completed.
02
Drugs
siltuximab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04191421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04191421.